14-6-10　ⓔ文献

  1. Berns JS, Rosner MH: Onco–nephrology: what the nephrologist needs to know about cancer and the kidney. Clin J Am Soc Nephrol, 2012; 7: 1691.

  2. Perazella MA: Onco–nephrology: renal toxicities of chemotherapeutic agents. Clin J Am Soc Nephrol, 2012; 7: 1713–1721.

  3. Christiansen CF, Johansen MB, et al: Incidence of acute kidney injury in cancer patients: a Danish population–based cohort study. Eur J Intern Med, 2011; 22: 399–406.

  4. Lam AQ, Humphreys BD: Onco–nephrology: AKI in the cancer patient. Clin J Am Soc Nephrol, 2012; 7: 1692–1700.

  5. Campbell GA, Hu D, et al: Acute kidney injury in the cancer patient. Adv Chronic Kidney Dis, 2014; 21: 64–71.

  6. Benoit DD, Hoste EA: Acute kidney injury in critically ill patients with cancer. Crit Care Clin, 2010; 26: 151–179.

  7. Ronco PM: Paraneoplastic glomerulopathies: new insights into an old entity. Kidney Int, 1999; 56: 355–377.

  8. Beck LH, Jr, Bonegio RG, et al: M–type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. New Engl J Med, 2009; 361: 11–21.

  9. Hoxha E, Wiech T, et al: A mechanism for cancer–associated membranous nephropathy. N Engl J Med, 2016; 374: 1995–1996.

  10. Cambier JF, Ronco P: Onco–nephrology: glomerular diseases with cancer. Clin J Am Soc Nephrol, 2012; 7: 1701–1712.

  11. Leung N, Bridoux F, et al: The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nat Rev Nephrol, 2019; 15: 45–59.

  12. Eremina V, Jefferson JA, et al: VEGF inhibition and renal thrombotic microangiopathy. New Eng J Med, 2008; 358: 1129–1136.

  13. Seethapathy H, Zhao S, et al: The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors. Clin J Am Soc Nephrol, 2019; 14: 1662–1700.

  14. Coiffier B, Altman A, et al: Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence–based review. J Clin Oncol, 2008; 26: 2767–2778.

  15. Hutchison CA, Batuman V, et al: The pathogenesis and diagnosis of acute kidney injury in multiple myeloma. Nature reviews. Nephrology, 2012; 8: 43–51.

  16. Hutchison CA, Cockwell P, et al: Early reduction of serum–free light chains associates with renal recovery in myeloma kidney. J Am Soc Nephrol, 2011; 22: 1129–1136.

  17. Lowrance WT, Ordonez J, et al: CKD and the risk of incident cancer. J Am Soc Nephrol, 2014; 25: 2327–2334.

  18. Maisonneuve P, Agodoa L, et al: Cancer in patients on dialysis for end–stage renal disease: an international collaborative study. Lancet, 1999; 354: 93–99.

  19. Holley JL: Screening, diagnosis, and treatment of cancer in long–term dialysis patients. Clin J Am Soc Nephrol, 2007; 2: 604–610.

  20. Launay–Vacher V, Oudard S, et al: Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer, 2007; 110: 1376–1384.